Literature DB >> 23204518

Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Yasuto Yamaguchi1, Zhifei Shao, Shadi Sharif, Xiao-Yan Du, Timothy Myles, Milton Merchant, Griffith Harsh, Michael Glantz, Lawrence Recht, John Morser, Lawrence L K Leung.   

Abstract

Osteopontin (OPN), which is highly expressed in malignant glioblastoma (GBM), possesses inflammatory activity modulated by proteolytic cleavage by thrombin and plasma carboxypeptidase B2 (CPB2) at a highly conserved cleavage site. Full-length OPN (OPN-FL) was elevated in cerebrospinal fluid (CSF) samples from all cancer patients compared with noncancer patients. However, thrombin-cleaved OPN (OPN-R) and thrombin/CPB2-double-cleaved OPN (OPN-L) levels were markedly increased in GBM and non-GBM gliomas compared with systemic cancer and noncancer patients. Cleaved OPN constituted ∼23 and ∼31% of the total OPN in the GBM and non-GBM CSF samples, respectively. OPN-R was also elevated in GBM tissues. Thrombin-antithrombin levels were highly correlated with cleaved OPN, but not OPN-FL, suggesting that the cleaved OPN fragments resulted from increased thrombin and CPB2 in this extracellular compartment. Levels of VEGF and CCL4 were increased in CSF of GBM and correlated with the levels of cleaved OPN. GBM cell lines were more adherent to OPN-R and OPN-L than OPN-FL. Adhesion to OPN altered gene expression, in particular genes involved with cellular processes, cell cycle regulation, death, and inflammation. OPN and its cleaved forms promoted motility of U-87 MG cells and conferred resistance to apoptosis. Although functional mutation of the RGD motif in OPN largely abolished these functions, OPN(RAA)-R regained significant cell binding and signaling function, suggesting that the SVVYGLR motif in OPN-R may substitute for the RGD motif if the latter becomes inaccessible. OPN cleavage contributes to GBM development by allowing more cells to bind in niches where they acquire anti-apoptotic properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23204518      PMCID: PMC3561533          DOI: 10.1074/jbc.M112.362954

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin.

Authors:  K J Bayless; G E Davis
Journal:  J Biol Chem       Date:  2001-01-25       Impact factor: 5.157

3.  The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin.

Authors:  Y Yokosaki; N Matsuura; T Sasaki; I Murakami; H Schneider; S Higashiyama; Y Saitoh; M Yamakido; Y Taooka; D Sheppard
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

4.  Protein disulfide isomerase mediates integrin-dependent adhesion.

Authors:  J Lahav; N Gofer-Dadosh; J Luboshitz; O Hess; M Shaklai
Journal:  FEBS Lett       Date:  2000-06-16       Impact factor: 4.124

5.  The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Y H Lin; H F Yang-Yen
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

Review 6.  Role of osteopontin in cellular signaling and toxicant injury.

Authors:  D T Denhardt; C M Giachelli; S R Rittling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

7.  Analysis of the alpha4beta1 integrin-osteopontin interaction.

Authors:  S T Barry; S B Ludbrook; E Murrison; C M Horgan
Journal:  Exp Cell Res       Date:  2000-08-01       Impact factor: 3.905

8.  Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins.

Authors:  P M Green; S B Ludbrook; D D Miller; C M Horgan; S T Barry
Journal:  FEBS Lett       Date:  2001-08-10       Impact factor: 4.124

9.  The role of thrombin in gliomas.

Authors:  Y Hua; L Tang; R F Keep; T Schallert; M E Fewel; K M Muraszko; J T Hoff; G Xi
Journal:  J Thromb Haemost       Date:  2005-06-24       Impact factor: 5.824

10.  Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.

Authors:  S Takano; K Tsuboi; Y Tomono; Y Mitsui; T Nose
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  22 in total

1.  Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells.

Authors:  Equar Taka; Elizabeth A Mazzio; Carl B Goodman; Natalie Redmon; Hernan Flores-Rozas; Renee Reams; Selina Darling-Reed; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2015-06-27       Impact factor: 3.478

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 3.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

4.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

5.  Identification of therapeutic targets for glioblastoma by network analysis.

Authors:  D Friedmann-Morvinski; V Bhargava; S Gupta; I M Verma; S Subramaniam
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

6.  Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?

Authors:  Ze'ev Itsekson-Hayosh; Efrat Shavit-Stein; David Last; David Goez; Dianne Daniels; Doron Bushi; Orna Gera; Zion Zibly; Yael Mardor; Joab Chapman; Sagi Harnof
Journal:  J Mol Neurosci       Date:  2015-02-19       Impact factor: 3.444

7.  Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Authors:  Felicitas Strehlow; Sandra Bauer; Peter Martus; Michael Weller; Patrick Roth; Uwe Schlegel; Sabine Seidel; Carmen Scheibenbogen; Agnieszka Korfel; Stephan Kreher
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

8.  Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients.

Authors:  Marco Quaglia; Annalisa Chiocchetti; Tiziana Cena; Claudio Musetti; Sara Monti; Nausicaa Clemente; Umberto Dianzani; Corrado Magnani; Piero Stratta
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980

9.  Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression.

Authors:  A Ellert-Miklaszewska; P Wisniewski; M Kijewska; P Gajdanowicz; D Pszczolkowska; P Przanowski; M Dabrowski; M Maleszewska; B Kaminska
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

10.  Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.

Authors:  Leonid Tarassishin; Jihyeon Lim; D Brent Weatherly; Ruth H Angeletti; Sunhee C Lee
Journal:  J Proteomics       Date:  2014-02-04       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.